Lourd Capital LLC bought a new position in Teleflex Incorporated (NYSE:TFX) during the 4th quarter, HoldingsChannel.com reports. The fund bought 1,071 shares of the medical technology company’s stock, valued at approximately $266,000.

A number of other institutional investors and hedge funds have also recently made changes to their positions in the stock. Clinton Group Inc. bought a new position in shares of Teleflex during the 2nd quarter worth about $325,000. Legal & General Group Plc increased its holdings in shares of Teleflex by 5.8% during the 3rd quarter. Legal & General Group Plc now owns 90,332 shares of the medical technology company’s stock worth $21,854,000 after purchasing an additional 4,929 shares during the period. Koch Industries Inc. increased its holdings in shares of Teleflex by 47,174.3% during the 2nd quarter. Koch Industries Inc. now owns 959,669 shares of the medical technology company’s stock worth $955,000 after purchasing an additional 957,639 shares during the period. Wealth Enhancement Advisory Services LLC bought a new position in shares of Teleflex during the 3rd quarter worth about $955,000. Finally, Atalanta Sosnoff Capital LLC bought a new position in shares of Teleflex during the 4th quarter worth about $280,000. Hedge funds and other institutional investors own 89.32% of the company’s stock.

Several research analysts have recently issued reports on the stock. Stephens restated a “buy” rating and set a $300.00 price objective on shares of Teleflex in a report on Thursday, January 18th. Morgan Stanley boosted their price objective on shares of Teleflex from $274.00 to $290.00 and gave the stock an “equal weight” rating in a report on Friday, November 3rd. ValuEngine downgraded shares of Teleflex from a “buy” rating to a “hold” rating in a report on Friday, December 1st. Piper Jaffray Companies assumed coverage on shares of Teleflex in a report on Friday, November 10th. They set an “overweight” rating and a $295.00 price objective on the stock. Finally, Jefferies Group boosted their price objective on shares of Teleflex from $270.00 to $295.00 and gave the stock a “buy” rating in a report on Friday, November 3rd. One investment analyst has rated the stock with a sell rating, five have given a hold rating and six have assigned a buy rating to the company’s stock. Teleflex has a consensus rating of “Hold” and a consensus target price of $277.78.

In related news, Director Stephen K. M.D. Klasko sold 200 shares of the company’s stock in a transaction dated Friday, December 1st. The shares were sold at an average price of $265.32, for a total value of $53,064.00. Following the sale, the director now owns 8,080 shares of the company’s stock, valued at $2,143,785.60. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, Director George Babich, Jr. sold 2,500 shares of the company’s stock in a transaction dated Tuesday, January 16th. The shares were sold at an average price of $263.38, for a total transaction of $658,450.00. Following the completion of the sale, the director now directly owns 10,583 shares in the company, valued at approximately $2,787,350.54. The disclosure for this sale can be found here. In the last three months, insiders sold 5,100 shares of company stock worth $1,324,942. 2.39% of the stock is currently owned by insiders.

Shares of Teleflex Incorporated (NYSE TFX) opened at $284.59 on Monday. The firm has a market cap of $12,820.00, a PE ratio of 51.37, a P/E/G ratio of 2.05 and a beta of 1.09. Teleflex Incorporated has a 52 week low of $162.79 and a 52 week high of $287.18. The company has a debt-to-equity ratio of 0.88, a current ratio of 4.72 and a quick ratio of 3.70.

Teleflex (NYSE:TFX) last posted its earnings results on Thursday, November 2nd. The medical technology company reported $2.12 earnings per share for the quarter, beating the Zacks’ consensus estimate of $2.01 by $0.11. The business had revenue of $534.70 million for the quarter, compared to analysts’ expectations of $522.94 million. Teleflex had a net margin of 12.41% and a return on equity of 16.27%. The firm’s revenue for the quarter was up 17.3% on a year-over-year basis. During the same quarter in the previous year, the firm posted $1.80 earnings per share. equities analysts expect that Teleflex Incorporated will post 8.36 EPS for the current year.

COPYRIGHT VIOLATION WARNING: This news story was first reported by The Cerbat Gem and is owned by of The Cerbat Gem. If you are reading this news story on another publication, it was illegally stolen and reposted in violation of international copyright & trademark laws. The correct version of this news story can be viewed at https://www.thecerbatgem.com/2018/01/29/lourd-capital-llc-buys-new-holdings-in-teleflex-incorporated-tfx.html.

Teleflex Company Profile

Teleflex Incorporated is a provider of medical technology products. The Company designs, develops, manufactures and supplies single-use medical devices used by hospitals and healthcare providers for diagnostic and therapeutic procedures in critical care and surgical applications. The Company operates through six segments: Vascular North America; Anesthesia North America; Surgical North America; Europe, the Middle East and Africa (EMEA); Asia, and Original Equipment Manufacturer (OEM).

Want to see what other hedge funds are holding TFX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Teleflex Incorporated (NYSE:TFX).

Institutional Ownership by Quarter for Teleflex (NYSE:TFX)

Receive News & Ratings for Teleflex Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teleflex and related companies with MarketBeat.com's FREE daily email newsletter.